Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heroin Dependence; Opioid-Related Disorders
Phase: Phase 1
Sponsored by: National Institute on Drug Abuse (NIDA)
Official(s) and/or principal investigator(s):
Mark Greenwald, PhD, Principal Investigator, Affiliation: Wayne State University
The purpose of this study is to determine whether knowledge of post-session hydromorphone
(HYD) availability reduces drug seeking behavior in heroin dependent individuals.
Official title: Biobehavioral Study of Opioid Drug Seeking Behavior: Study 2
Study design: Prospective
Drug dependence is often characterized by severe drug seeking behavior. Learning to
understand, predict, and control this maladaptive choice behavior may lead to improved
prevention and treatment strategies. HYD is a drug that is currently used as a cough
suppressant and to relieve pain. The purpose of this study is to determine the extent to
which opioid drug seeking behavior by heroin dependent individuals can be reduced by
environmental factors, including supplemental opioid drug availability, drug price, and
alternative non-drug reinforcers. Specifically, this study will determine whether knowledge
of post-session HYD availability influences drug seeking behavior in heroin dependent
individuals, who are maintained on buprenorphine during their participation.
Participants in this observational study will take part in multiple trials in which they have
the opportunity to choose either HYD or money. On the first two experimental days, prior to
choice sessions, participants will receive a sample of the drug doses that can be chosen.
During test sessions, participants will have 12 opportunities to choose either drug or money.
Participants will use a computer to earn choices. Respiration rate, oxygen saturation,
heart rate, and blood pressure will be monitored throughout choice trials. Supplemental HYD
will be made available following some choice sessions. Self-report questionnaires will be
completed at different times during the study. Participants will be maintained on
buprenorphine throughout the study, with a minimum 2-week lead before the experiment, and a
fixed 3-week detoxification after study completion.
Minimum age: 18 Years.
Maximum age: 55 Years.
- Opioid dependent, as determined by the structured clinical interview for DSM-IV (SCID)
and Addiction Severity Index (ASI)
- Positive urine test for opiates
- Willing to use an adequate form of contraception for the duration of the study
- Reads and writes English
- Psychiatric illness, as determined by the DSM-IV criteria
- History of or current neurological disease, including structural abnormalities,
seizures, infection, peripheral neuropathy, and head traumas
- History of cardiovascular disease, myocardial infarction, chest pain, or edema
- Systolic blood pressure greater than 160 mm Hg or less than 95 mm Hg; PR diastolic
blood pressure greater than 95 mm Hg
- Pulmonary disease, including obstructive pulmonary disease, cor pulmonale,
tuberculosis, and asthma
- Systemic disease (e. g., endocrinopathies, liver or kidney failure, myxedema,
hypothyroidism, Addison's disease, autoimmune disease)
- Current alcohol or sedative drug dependence
- Pregnant or breastfeeding
- Currently receiving treatment for opioid dependence
- Known phobia of injections
Locations and Contacts
Wayne State University, Detroit, Michigan 48207, United States
Starting date: August 2005
Last updated: April 9, 2008